The study, published in Annals of the Rheumatic Diseases, found that patients receiving Humira for 12 weeks experienced a significant improvement in spine and sacroiliac joint inflammation compared with those who received the placebo. Approximately 36 percent of patients taking Humira reported experiencing at least a 40 percent improvement in pain, compared to 15 percent taking the placebo.    

The effects also appeared to have long-term benefits for patients. Nearly one-quarter of the Humira group experienced clinical remission after three months, compare with four percent of the placebo group.  

Related Articles on Pain Management:

ASIPP Releases Opioid Guidelines
Study: Pediatric Pain Rehab Boosts Self-Management Skills
PainCare to Open Twelfth Location